Crown Bioscience announced new data further characterizing and enhancing the immunocompetent models included in their large-scale immunotherapy screening platform, MuScreen.
The strategic merger integrates Crown Bioscience’s leading translational technology platform providing drug target validation, efficacy testing and patient response characterization with JSR’s in v...
As a premier contract research organization (CRO), CrownBio has deep industry relationships and a global footprint that will complement JSR’s already global presence.
Recently published work in the Journal of Endocrinological Investigation and Nature’s Scientific Reports demonstrates the advantages of a new method using DSI’s HD-XG implantable glucose device and...
These joint publications illustrate the utility of Crown Bioscience’s proprietary FATZO model as a model for obesity and type 2 diabetes in preclinical studies.
The data derived from studies using CrownBio’s portfolio showed the immunotherapy’s potential clinical utility and demonstrated the benefits of using CrownBio’s platform in preclinical efficacy tes...
7 of 11
Receive JSR Life Sciences news on your RSS reader.
